Urolithin A vs Sulforaphane
Urolithin A and sulforaphane are both plant-born compounds with serious science behind them, and both touch how cells defend and maintain themselves. But they act at different control points: urolithin A helps cells recycle worn mitochondria, while sulforaphane flips on the Nrf2 switch that tells cells to build their own antioxidant defenses. Knowing which lever each one pulls makes the choice much clearer.
This comparison lays out what each compound is, where they come from, how the mechanisms genuinely differ, and what human trials support versus what is still preclinical. For a complete primer on the first compound, start with our urolithin A guide.
Recycling machinery versus arming the defenses
Sulforaphane is an isothiocyanate produced when you crush or chew cruciferous vegetables - broccoli sprouts are the richest source, with the sprout enzyme myrosinase converting a precursor called glucoraphanin into active sulforaphane. Its signature action is activating the Nrf2 pathway. Nrf2 is a transcription factor that, when switched on, prompts the cell to produce its own arsenal of antioxidant and detoxification enzymes, including glutathione-related systems. So sulforaphane does not act as an antioxidant itself so much as it instructs the cell to manufacture its own defenses - an indirect but potentially durable effect.
Urolithin A operates on a different system entirely. It is a gut postbiotic: your microbiome makes it from ellagitannins found in pomegranate, walnuts, and berries, though only some people host the bacteria that perform the conversion efficiently. Once in the body, urolithin A supports mitophagy - the housekeeping process by which cells identify and recycle worn or damaged mitochondria so healthier ones can replace them. Mitochondria generate the energy your cells run on, and their quality tends to erode with age. To understand that renewal process, see what is mitophagy and mitochondrial health.
Put simply: sulforaphane tells the cell to build defenses (Nrf2 activation), while urolithin A helps the cell clean house and renew its power plants (mitophagy). Both aim at resilient, well-functioning cells, but through non-overlapping routes.
Human evidence compared
Urolithin A: proven human findings first
The urolithin A human record is compact and consistent. The first-in-human trial by Andreux and colleagues (2019, Nature Metabolism) showed the compound was safe and well tolerated up to 1,000 mg per day and shifted mitochondrial gene expression in older adults. Two randomized controlled trials then examined muscle: Liu, D'Amico and colleagues (2022, JAMA Network Open) found improved muscle endurance in older adults over about four months, and Singh and colleagues (2022, Cell Reports Medicine) reported gains in muscle strength and exercise performance in middle-aged adults over four months across 500 mg and 1,000 mg arms.
Newer human work broadens this: a 2024 randomized trial in the Journal of the International Society of Sports Nutrition studied resistance-trained men over eight weeks, a 2025 trial looked at distance runners, and a 2025 Nature Aging study (a roughly 28-day RCT) reported support for immune-cell mitochondrial health in midlife adults, connected to the concept of inflammaging. A 2024 systematic review in Ageing Research Reviews summarized the human evidence as still emerging. For a fuller tour, see urolithin A clinical studies.
Sulforaphane: promising signals, evolving picture
Sulforaphane has a substantial mechanistic literature and a growing set of human studies. In people, broccoli-sprout preparations have been shown to induce Nrf2 target genes and support the body's detoxification enzyme systems, and researchers have measured shifts in relevant biomarkers. At the same time, reviews of Nrf2 activators have cautioned that clinician expectations sometimes outrun the clinical reality: sulforaphane content varies enormously between products depending on whether active myrosinase is present, absorption is inconsistent, and many human endpoints remain preliminary. The mechanism is well characterized; the translation into specific, reproducible human outcomes is still maturing.
The fair comparison: urolithin A has a tighter cluster of controlled trials focused on muscle and mitochondrial measures, while sulforaphane has strong mechanistic grounding for Nrf2 activation but a more variable and formulation-dependent human record.
What remains preclinical
Both compounds have vivid early research that should be read as open questions. For urolithin A, the foundational mechanism work is preclinical: Ryu and colleagues (2016, Nature Medicine) demonstrated mitophagy, extended lifespan in the worm C. elegans, and improved muscle measures in rodents, and D'Amico and colleagues (2022, Aging Cell) studied joint and cartilage outcomes in osteoarthritis models. Directions such as skin, gut, brain, and heart are at the early or preclinical stage where research is still exploring.
Sulforaphane likewise carries a large preclinical body across neurological, metabolic, and detoxification models. As always, striking effects in cells and animals frequently shrink in rigorous human trials. Reading the preclinical material for both compounds as a set of hypotheses - not a benefits list - keeps expectations honest.
Practical guidance
Choose urolithin A if your focus is energy and muscle
The human trials for urolithin A cluster around muscle endurance, strength, and mitochondrial measures, which makes it the more targeted pick for people prioritizing cellular energy and physical performance as they age. Studied doses run 500 to 1,000 mg per day, with 1,000 mg at the top, and benefits accrued over weeks to months - see how long urolithin A takes to work and urolithin A for energy.
Consider sulforaphane if your focus is antioxidant defense signaling
If you are specifically interested in supporting the Nrf2 pathway and the body's own antioxidant and detoxification enzymes, sulforaphane is the compound built around that mechanism - just prioritize a product with verified active content, since potency varies widely.
Using both
Because mitophagy and Nrf2 activation are distinct systems, there is no obvious biological conflict in combining them, and some people do. But no human trial has tested this pairing for added benefit, so the rationale is theoretical. Importantly, neither compound is a treatment for any disease, and neither is a detox program in the medical sense - the body's own enzyme systems do that work. If you take medications or have a health condition, decide with your doctor rather than from a label. This guidance is educational and not a substitute for individualized medical advice; see your doctor for anything health-related.
Frequently asked questions
What is the main difference between urolithin A and sulforaphane?
Urolithin A supports mitophagy, the recycling of worn mitochondria. Sulforaphane activates the Nrf2 pathway, prompting cells to build their own antioxidant and detoxification enzymes. They act on different systems and are not interchangeable.
Does sulforaphane support mitochondria the way urolithin A does?
Not in the same direct way. Sulforaphane works mainly through Nrf2-driven antioxidant defenses, while urolithin A works on the quality control and renewal of mitochondria themselves. Their targets overlap in spirit but not in mechanism.
Can I take urolithin A and sulforaphane together?
Their mechanisms are separate, so there is no obvious conflict, and some people combine them. However, no human study has tested this specific pairing for added benefit, so any stacking rationale is theoretical. Check with your doctor, especially if you take medications.
Which has stronger human evidence?
Urolithin A has a tighter set of randomized trials focused on muscle and mitochondrial endpoints. Sulforaphane has strong mechanistic grounding for Nrf2 activation but a more variable, formulation-dependent human record. Both are areas of active research.
Why supplement urolithin A instead of eating pomegranate or walnuts?
Only some people carry the gut bacteria that convert ellagitannins into meaningful urolithin A. Supplementing delivers the finished compound directly. The human trials used 500 to 1,000 mg per day, hard to reach through diet alone. See foods high in urolithin A.
Is either compound a detox or a disease treatment?
No. Both are studied for structure and function support only. Neither is intended to diagnose, treat, cure, or prevent any disease. If you have a health concern, see your doctor.
What urolithin A dose is worth considering?
Human trials studied 500 to 1,000 mg per day, with 1,000 mg at the top of the range. For more detail see urolithin A dosage and compare products at best urolithin A gummies.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.
A clinically studied 1,000 mg dose of Urolithin A in one simple daily gummy — to support mitophagy, muscle strength, and cellular energy.
Shop SOMA Urolithin A Gummies →